Indonesia Prothrombin Complex Concentrate (PCC) Market Outlook

indonesia prothrombin complex concentrate (pcc) market outlook is expected to be healthy for the coming years with significant growth opportunities in the healthcare sector. this can be attributed to a growing consumer base for high-end medical products and services, in line with the increasing life expectancy in the country. furthermore, changing reimbursement policies and regulations, wider insurance reach, an expanding middle-class population, and the increasing availability of advanced medical treatments are all expected to drive the demand for pcc in the country. in terms of usage, pcc is primarily used in the management and treatment of a variety of bleeding disorders such as hemophilia and von willebrand disease. it is also used to treat some conditions caused by a lack of protein c and is sometimes used as a complement to oral anticoagulant therapy in the prevention of strokes. its efficacy in treating other disorders such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation (dic) have also been reported. currently, pccs are derived from plasma-derived sources such as human plasma, or manufactured as plasma-derived products such as cryoprecipitates, and recombinant sources such as purified factor ix, or human plasma-coated vesicles. the use of pccs has been increasing due to its cost effectiveness and ability to provide immediate hemostatic protection with appropriate measurements. it is important to note that there have been concerns about potential safety issues with plasma derived products that could limit their use in some instances. in terms of pricing, pccs are currently sold either as a single dose or in multi-dose vials for multiple administrations. multi-dose vial product prices have been decreasing due to competition from other producers, while single dose administration costs may rise due to its convenience and lower wastage rate. the overall outlook for the indonesian pcc market looks strong and the market is expected to experience steady growth of about 8-10% during 2018-2032. the main drivers of this growth are expected to be increasing healthcare spending, a growing population, aging demographics and the growing awareness of advanced treatments among the public. in addition, government initiatives to provide universal healthcare to all citizens, continued medical insurance coverage, advancements in technology and quick delivery options, and the increasing popularity of e-commerce will further spur demand.